 |
Email the Society |
 |
Donations |
ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
Mailing address:
GPO Box 383,
Adelaide,
South Australia 5001
Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: (08) 8346 3237
('834 MECFS')
Office Hours:
Wednesdays, 10am-3pm
Support Line:
(Mondays and Thursdays,
10am-3pm)
Ph: (08) 8346 3237
SA country callers:
Ph: 1300 128 339
(local call)
FIBROMYALGIA HELP: Contact Fibromyalgia SA at the Arthritis Foundation of SA 118 Richmond Road, Marleston 5033 Ph: (08) 8379 5711 |
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
|
Disclaimer
ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
| Become a Member | |||
|
Ampligen for Chronic Fatigue Syndrome: still a possibility
Thursday 26 January 2012
From About.com's Adrienne Dellwo:
Ampligen for Chronic Fatigue Syndrome: Still a Possibility
NEWSBRIEF: After being rejected 2 years ago, the drug that many thought would become the first FDA-approved treatment for chronic fatigue syndrome (ME/CFS) apparently isn't off the table. Hemispherx Biopharma Inc. says the FDA has granted an extension that could allow them to make another run at getting Ampligen (rintatolimod) approved.
Here's a little about how the process works: drug companies trying to get a new product approved submit a New Drug Application (NDA) to the FDA. A rejection doesn't mean, "No, go away." It's more of a, "Not based on the current application." When Ampligen was rejected in December 2009, the FDA detailed for the company what more it would need in order to strengthen its application. The company then has a limited time to submit information under the NDA. Ampligen's NDA was due to expire, but now the company has more time to get information in without having to start a new NDA.
Ampligen is a controversial drug. For more than 3 decades, it's been tested against a wide array of illnesses with little success. However, results were better with ME/CFS. Critics say the company is desperately trying to make some money on a failed project. However, research has showed promise. For the few people who've been allowed, under special conditions, to take Ampligen, results are mixed - some have no improvement or can't tolerate the drug, while some feel better. That's true of any ME/CFS treatment, and I suspect it will be until we have proper subgrouping. (Many researchers believe that several types of ME/CFS exist that each need a different treatment protocol.)
Ampligen is an immune-system modulator and anti-viral. It's believed to work by jump-starting your body's natural anti-viral pathway.
Learn more or join the conversation!
NEWSLETTER | FORUM | BIO | TWITTER | FACEBOOK
• ME/CFS, Viruses & the Immune System
• ME/CFS Treatment Options
• What Causes ME/CFS?
The above, with comments, originally appeared here.
blog comments powered by Disqus
Previous Page |
